Home » Stocks » OSMT

Osmotica Pharmaceuticals PLC (OSMT)

Stock Price: $3.12 USD -0.02 (-0.64%)
Updated Apr 23, 2021 9:53 AM EDT - Market open
Market Cap 198.19M
Revenue (ttm) 177.88M
Net Income (ttm) -79.59M
Shares Out 60.65M
EPS (ttm) -1.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 23
Last Price $3.12
Previous Close $3.14
Change ($) -0.02
Change (%) -0.64%
Day's Open 3.12
Day's Range 3.11 - 3.15
Day's Volume 10,534
52-Week Range 2.95 - 9.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, April 8, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ: OSMT).  Such investors are ad...

2 weeks ago - PRNewsWire

Shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) decreased after the company reported Q4 results. Quarterly Results Earnings per share decreased 1566.67% over the past year to ($0.88), which missed the ...

3 weeks ago - Benzinga

Fourth quarter and full year 2020 total revenue of $34.5 million and $177.9 million, respectively

3 weeks ago - GlobeNewsWire

BRIDGEWATER, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Co...

4 weeks ago - GlobeNewsWire

BRIDGEWATER, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian ...

1 month ago - GlobeNewsWire

BRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian M...

2 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Ap9

2 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Ap9

2 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- fAp9

2 months ago - GlobeNewsWire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

2 months ago - GlobeNewsWire

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: KGC, NDLS, TACO, WIMI
3 months ago - 24/7 Wall Street

One of the company's pipeline candidates ran into a regulatory hurdle.

3 months ago - The Motley Fool

BRIDGEWATER, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issu...

3 months ago - GlobeNewsWire

Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple scleros...

Other stocks mentioned: AYTU, KNTE, MYOV
3 months ago - Benzinga

Adamas to acquire global rights to OSMOLEX ER® for $7.5 million

4 months ago - GlobeNewsWire

-- Addition of Dr. Raymond Douglas, M.D., PhD, further enhances RVL's commitment to advancing the clinical and scientific platform supporting Upneeq -- -- Addition of Dr. Raymond Douglas, M.D., PhD, fur...

5 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian M...

5 months ago - GlobeNewsWire

Osmotica Pharmaceuticals' (OSMT) CEO Brian Markison on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) rose 4.4% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 148.28% year over year to ($0.14)...

5 months ago - Benzinga

Third quarter 2020 total revenue of $57.2 million

5 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Com...

5 months ago - GlobeNewsWire

-- Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acquired ptosis...

6 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Bria...

7 months ago - GlobeNewsWire

Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 0.00% and -2.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) decreased 4.46% in after-market trading after the company reported Q2 results.

8 months ago - Benzinga

Second quarter 2020 total revenue of $37.5 million

8 months ago - GlobeNewsWire

-Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO- -Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO-

8 months ago - GlobeNewsWire

OSMOTICA PHARM (OSMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

OSAKA, Japan and BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd (hereinafter, Santen) and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (...

8 months ago - GlobeNewsWire

BRIDGEWATER, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) through its subsidiary Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a fully integrated...

9 months ago - GlobeNewsWire

The company announced the pricing of a public offering of common stock.

9 months ago - The Motley Fool

BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the pricin...

9 months ago - GlobeNewsWire

BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the commen...

9 months ago - GlobeNewsWire

Osmotica Pharmaceuticals (NASDAQ: OSMT) surged Friday, ending the day up 25.3% to close at $8.77 per share.

9 months ago - Benzinga

One of the company’s promising products was approved by the FDA.

9 months ago - The Motley Fool

-- First and only FDA-approved pharmacologic treatment for acquired blepharoptosis -- -- Company to host Investor Call at 10:00 a.m. ET today to discuss approval, key elements of the clinical data and ...

9 months ago - GlobeNewsWire

-- Submission based on world’s largest database of patients treated for spasticity associated with Multiple Sclerosis -- -- Demonstrated efficacy, tolerability and one-year safety results on 80 mg/day --

9 months ago - GlobeNewsWire

Osmotica Pharmaceuticals (OSMT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

BRIDGEWATER, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian...

10 months ago - GlobeNewsWire

BRIDGEWATER, N.J., May 27, 2020 /PRNewswire/ -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced results of the Co...

10 months ago - PRNewsWire

Osmotica Pharmaceuticals PLC (OSMT) CEO Brian Markison on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 58.33% and 11.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

First quarter 2020 total revenue of $48.6 million

11 months ago - GlobeNewsWire

OSMOTICA PHARM (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 500.00% and 11.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Insider buying can be an encouraging signal for potential investors. Insiders at some small-cap biotechs have made notable share purchases.

Other stocks mentioned: APTX, LJPC
1 year ago - Benzinga

OSMT vs. ILMN: Which Stock Is the Better Value Option?

Other stocks mentioned: ILMN
1 year ago - Zacks Investment Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

1 year ago - Zacks Investment Research

About OSMT

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
OSMT
Full Company Profile

Financial Performance

In 2020, OSMT's revenue was $177.88 million, a decrease of -25.89% compared to the previous year's $240.03 million. Losses were -$79.59 million, -70.62% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for OSMT stock is "Buy." The 12-month stock price forecast is 7.75, which is an increase of 148.40% from the latest price.

Price Target
$7.75
(148.40% upside)
Analyst Consensus: Buy